March 23rd, 2015
Dangerous Interaction: New Hepatitis C Drug and Old Arrhythmia Drug
Larry Husten, PHD
Late last week Gilead Sciences issued a warning about a rare but potentially fatal interaction between its stellar new hepatitis C drug sofosbuvir and amiodarone, a potent but tricky antiarrhythmic agent. Sofosbuvir is marketed as Sovaldi and, in combination with another antiviral agent, as Harvoni. Amiodarone is a class III antiarrhythmic with a number of […]
NEJM Journal Watch — Recent Cardiology Articles- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Sessions 2024
- Does the Coronary Sinus Reducer Decrease Ischemia and Angina in Patients with Stable Coronary Disease?
- Plozasiran Reduced Triglyceride Levels in Severe Hypertriglyceridemia
- Managing Elevated Blood Pressure in Hospitalized Patients